Breast Cancer

Funding Awarded for Antibody Development

Published in Cancer Weekly, July 4th, 2000

Tularik Inc. (TLRK), San Francisco, California, announced that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the U.S. National Institutes of Health.

This Phase I grant, entitled "Antibodies to New Amplified Breast Cancer Gene Products," supports research to create antibodies to novel amplified breast cancer gene products that will be used for immunochemical assays.

Tularik uses Representational Difference Analysis (RDA), a proprietary technique, in combination with other technology to discover cancer genes (oncogenes) that are amplified at the DNA level. The ultimate goal of this project...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry